A Multiple Dose Escalation Study in Chinese Participants With Overweight BMI or Obesity to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943
Latest Information Update: 16 Aug 2023
At a glance
- Drugs Retatrutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 10 Aug 2023 Status changed from active, no longer recruiting to completed.
- 23 May 2023 Planned End Date changed from 15 Jun 2023 to 31 Jul 2023.
- 23 May 2023 Planned primary completion date changed from 15 Jun 2023 to 31 Jul 2023.